Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH-An update

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 1, 2014, Pages 18-29

  Gazzaruso, Carmine ^b   Gola, Monica ^c   Karamouzis, Ioannis ^a   Giubbini, Raffaele ^a   Giustina, Andrea ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

^c Mirandola Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG DOSE TITRATION; ENDOTHELIAL DYSFUNCTION; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HEART FUNCTION; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; THROMBOSIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CARDIOVASCULAR DISEASES; GLUCOSE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INSULIN RESISTANCE; RISK FACTORS;

EID: 84892144329     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2394     Document Type: Article

References (146)

1. Rosilio M, Blum WF, Edwards DJ, et al. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab. 2004; 89(4):1684-1693.
2. Koltowska-Häggström M, Mattsson AF, Shalet SM. Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. Eur J Endocrinol. 2009;161(suppl 1):S51-S64.
3. Jørgensen AP, Fougner KJ, Ueland T, et al. Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency. Growth Horm IGF Res. 2011;21(2):69-75.
4. Widdowson WM, Gibney J. The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis. J Clin Endocrinol Metab. 2008;93(11):4413-4417.
5. Doga M, Bonadonna S, Gola M, Mazziotti G, Nuzzo M, Giustina A. GH deficiency in the adult and bone. J Endocrinol Invest. 2005; 28(8):18-23.
6. Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab. 1994;78:669-674.
7. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357(9):905-916.
8. Rosén T, Hansson T, Granhed H, Szucs J, Bengtsson BA. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh). 1993;129:201-206.
9. Gola M, Bonadonna S, Doga M, Giustina A. Clinical review: growth hormone and cardiovascular risk factors. J Clin Endocrinol Metab. 2005;90(3):1864-1870.
10. Gola M, Giustina A. Growth hormone deficiency and cardiovascular risk: do we need additional markers? Endocrine. 2012;42(2): 240-242.
11. Abdu TA, Neary R, Elhadd TA, Akber M, Clayton RN. Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities. Clin Endocrinol (Oxf). 2001;55(2):209-216.
12. Gazzaruso C, Coppola A, Montalcini T, et al. Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus. Endocrine. 2012;41(1):89-95.
13. Gazzaruso C, Garzaniti A, Falcone C, Geroldi D, Finardi G, Fratino P. Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary artery disease in type 2 diabetic patients and in non-diabetic subjects. Diabet Med. 2001;18(7):589-594.
14. Robinson JG, Wang S, Jacobson TA. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol. 2012;110(10):1468-1476.
15. Svensson J, Fowelin J, Landin K, Bengtsson BA, Johansson JO. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab. 2002;87(5):2121-2127.
16. van der Klaauw AA, Romijn JA, Biermasz NR, et al. Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. Eur J Endocrinol. 2006;155(5):701-708.
17. Götherström G, Svensson J, Koranyi J, et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab. 2001;86(10):4657-4665.
18. Colson A, Brooke AM, Walker D, et al. Growth hormone deficiency and replacement in patients with treated Cushing's disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density. Horm Res. 2006;66(6):257-267.
19. Florakis D, Hung V, Kaltsas G, et al. Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. Clin Endocrinol (Oxf). 2000;53(4):453-459.
20. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. J Clin Endocrinol Metab. 2004;89(5):2192-2199.
21. Elbornsson M, Götherström G, Bosæus I, Bengtsson BÅ, Johannsson G, Svensson J. Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol. 2013;168(5):745-753.
22. Chrisoulidou A, Beshyah SA, Rutherford O, et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab. 2000;85(10):3762-3769.
23. Spielhagen C, Schwahn C, Möller K, et al. The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database. Growth Horm IGF Res. 2011;21(1):1-10.
24. Stalenhoef AF, de Graaf J. Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipidol. 2008;19(4):355-361.
25. Rizzo M, Trepp R, Berneis K, Christ ER. Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy. Eur J Endocrinol. 2007;156(3):361-367.
26. Salman S, Uzum AK, Telci A, Alagol F, Ozbey NC. Serum adipokines and low density lipoprotein subfraction profile in hypopituitary patients with growth hormone deficiency. Pituitary. 2012; 15(3):386-392.
27. Monson JP, Jönsson P, Koltowska-Häggström M, Kourides I. Growth hormone (GH) replacement decreases serum total and LD Lcholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy. Clin Endocrinol (Oxf). 2007; 67(4):623-628.
28. Hwu CM, Kwok CF, Lai TY, et al. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J Clin Endocrinol Metab. 1997;82(10):3285-3292.
29. Yuen KC, Dunger DB. Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults. Growth Horm IGF Res. 2006;16(suppl A):S55-S61.
30. Bülow B, Link K, Ahrén B, Nilsson AS, Erfurth EM. Survivors of childhood acute lymphoblastic leukaemia, with radiation-induced GH deficiency, exhibit hyperleptinaemia and impaired insulin sensitivity, unaffected by 12 months of GH treatment. Clin Endocrinol (Oxf). 2004;61(6):683-691.
31. Hana V, Silha JV, Justova V, Lacinova Z, Stepan JJ, Murphy LJ. The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance. Clin Endocrinol (Oxf). 2004;60(4):442-450.
32. Bramnert M, Segerlantz M, Laurila E, Daugaard JR, Manhem P, Groop L. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. J Clin Endocrinol Metab. 2003;88(4):1455-1463.
33. Gillberg P, Bramnert M, Thorén M, Werner S, Johannsson G. Commencing growth hormone replacement in adults with a fixed low dose. Effects on serum lipoproteins, glucose metabolism, body composition, and cardiovascular function. Growth Horm IGF Res. 2001;11(5):273-281.
34. Arwert LI, Roos JC, Lips P, Twisk JW, Manoliu RA, Drent ML. Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men. Clin Endocrinol (Oxf). 2005;63(3):310-316.
35. Spina LD, Soares DV, Brasil RR, Lobo PM, Lúcia Conceição F, Vaisman M. Glucose metabolism and visceral fat in GH deficient adults: two years of GH-replacement. Pituitary. 2004;7(3):123-129.
36. Boguszewski CL, Meister LH, Zaninelli DC, Radominski RB. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur J Endocrinol. 2005;152(1):67-75.
37. Spina LD, Soares DV, Brasil RR, et al. Glucose metabolism and visceral fat in GH deficient adults: 1 year of GH replacement. Growth Horm IGF Res. 2004;14(1):45-51.
38. Cenci MC, Conceição FL, Soares DV, et al. Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults. Metabolism. 2008;57(1):121-129.
39. Roemmler J, Kuenkler M, Schneider HJ, Dieterle C, Schopohl J. Comparison of glucose and lipid metabolism and bone mineralization in patients with growth hormone deficiency with and without long-term growth hormone replacement. Metabolism. 2010;59(3): 350-358.
40. Oliveira CR, Salvatori R, Barreto-Filho JA, et al. Insulin sensitivity andβ-cell function in adults with lifetime, untreated isolated growth hormone deficiency. J Clin Endocrinol Metab. 2012;97(3):1013-1019.
41. Giavoli C, Porretti S, Ronchi CL, et al. Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy. Metabolism. 2004;53(6):740-743.
42. Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med. 2000;133(2):111-122.
43. Beauregard C, Utz AL, Schaub AE, et al. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008;93(6):2063-2071.
44. Arafat AM, Möhlig M, Weickert MO, Schöfl C, Spranger J, Pfeiffer AF. Improved insulin sensitivity, preserved beta cell function and improved whole-body glucose metabolism after low-dose growth hormone replacement therapy in adults with severe growth hormone deficiency: a pilot study. Diabetologia. 2010;53(7):1304-1313.
45. Nikolopoulou A, Kadoglou NP. Obesity and metabolic syndrome as related to cardiovascular disease. Expert Rev Cardiovasc Ther. 2012;10(7):933-939.
46. Ma X, Zhu S. Metabolic syndrome in the prevention of cardiovascular diseases and diabetes-still a matter of debate? Eur J Clin Nutr. 2013;67(5):518-521.
47. Gazzaruso C, Solerte SB, De Amici E, et al. Association of the metabolic syndrome and insulin resistance with silent myocardial ischemia in patients with type 2 diabetes mellitus. Am J Cardiol. 2006; 97(2):236-239.
48. van der Klaauw AA, Biermasz NR, Feskens EJ, et al. The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur J Endocrinol. 2007;156(4):455-462.
49. Attanasio AF, Mo D, Erfurth EM, et al. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab. 2010;95(1):74-81.
50. Ukropec J, Penesová A, Skopková M, et al. Adipokine protein expression pattern in growth hormone deficiency predisposes to the increased fat cell size and the whole body metabolic derangements. J Clin Endocrinol Metab. 2008;93(6):2255-2262.
51. Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab. 2006;91(10):3954-3961.
52. Abs R, Feldt-Rasmussen U, Mattsson AF, et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. Eur J Endocrinol. 2006;155(1):79-90.
53. Götherström G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab. 2007; 92(4):1442-1445.
54. Colao A, Di Somma C, Spiezia S, et al. Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J Clin Endocrinol Metab. 2008;93(9):3416-3424.
55. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2005;48(9):1684-1699.
56. Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia. 2010;53(4):600-605.
57. Vahl N, Juul A, Jørgensen JO, Orskov H, Skakkebaek NE, Christiansen JS. Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study. J Clin Endocrinol Metab. 2000;85(5):1874-1881.
58. Johannsson G, Albertsson-Wikland K, Bengtsson BA. Discontinuation of growth hormone (GH) treatment: metabolic effects in GHdeficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for GrowthHormone Treatment in Children. J Clin Endocrinol Metab. 1999;84(12):4516-4524.
59. Attanasio AF, Shavrikova E, Blum WF, et al. Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients. J Clin Endocrinol Metab. 2004;89(10):4857-4862.
60. Tauber M, Jouret B, Cartault A, et al. Adolescents with partial growth hormone (GH) deficiency develop alterations of body composition after GH discontinuation and require follow-up. J Clin Endocrinol Metab. 2003;88(11):5101-5106.
61. Mauras N, Pescovitz OH, Allada V, Messig M, Wajnrajch MP, Lippe B. Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial. J Clin Endocrinol Metab. 2005;90(7):3946-3955.
62. Rietzschel E, De Buyzere M. High-sensitive C-reactive protein: universal prognostic and causative biomarker in heart disease? Biomark Med. 2012;6(1):19-34.
63. Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ES, Kastelein JJ. C-reactive protein is a mediator of cardiovascular disease. Eur Heart J. 2010;31(17):2087-2091.
64. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327-334.
65. Hu G, Jousilahti P, Tuomilehto J, Antikainen R, Sundvall J, Salomaa V. Association of serum C-reactive protein level with sex-specific type 2 diabetes risk: a prospective Finnish study. J Clin Endocrinol Metab. 2009;94(6):2099- 2105.
66. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290(22):2945-2951.
67. Yang T, Chu CH, Hsieh PC, et al. C-reactive protein concentration as a significant correlate for metabolic syndrome: a Chinese population-based study. Endocrine. 2013;43(2):351-359.
68. Lee SD, Huang CY, Shu WT, et al. Pro-inflammatory states and IGF-I level in ischemic heart disease with low or high serum iron. Clin Chim Acta. 2006;370(1-2):50-56.
69. McCallum RW, Sainsbury CA, Spiers A, et al. Growth hormone replacement reduces C-reactive protein and large-artery stiffness but does not alter endothelial function in patients with adult growth hormone deficiency. Clin Endocrinol (Oxf). 2005;62(4):473-479.
70. Bollerslev J, Ueland T, Jørgensen AP, et al. Positive effects of a physiological dose of GH on markers of atherogenesis: a placebocontrolled study in patients with adult-onset GH deficiency. Eur J Endocrinol. 2006;154(4):537-543.
71. Sesmilo G, Miller KK, Hayden D, Klibanski A. Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab. 2001;86(12):5774-5781.
72. Deepak D, Daousi C, Javadpour M, et al. The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency. Growth Horm IGF Res. 2010;20(3):220-225.
73. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045-2051.
74. Wong BW, Meredith A, Lin D, McManus BM. The biological role of inflammation in atherosclerosis. Can J Cardiol. 2012;28(6):631-641.
75. Serri O, St-Jacques P, Sartippour M, Renier G. Alterations of monocyte function in patients with growth hormone (GH) deficiency: effect of substitutive GH therapy. J Clin Endocrinol Metab. 1999; 84(1):58-63.
76. Andiran N, Yordam N. TNF-alpha levels in children with growth hormone deficiency and the effect of long-term growth hormone replacement therapy. Growth Horm IGF Res. 2007;17(2):149-153.
77. Pardo M, Roca-Rivada A, Seoane LM, Casanueva FF. Obesidomics: contribution of adipose tissue secretome analysis to obesity research. Endocrine. 2012;41(3):374-383.
78. Sahin-Efe A, Katsikeris F, Mantzoros CS. Advances in adipokines. Metabolism. 2012;61(12):1659-1665.
79. Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V, Murphy BD, Palin MF. Adiponectin action from head to toe. Endocrine. 2010;37(1):11-32.
80. Kim HS, Jo J, Lim JE, et al. Adiponectin as predictor for diabetes among pre-diabetic groups. [published online ahead of print February 06, 2013] Endocrine. doi:10.1007/s12020-013-9890-5.
81. Chaves VE, Júnior FM, Bertolini GL. The metabolic effects of growth hormone in adipose tissue. Endocrine. 2013;44(2):293-302.
82. Miyakawa M, Tsushima T, Murakami H, Isozaki O, Demura H, Tanaka T. Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab. 1998;83(10):3476- 3479.
83. Giavoli C, Cappiello V, Corbetta S, et al. Different effects of shortand long-term recombinanth GH administration on ghrelin and adiponectin levels in GH-deficient adults. Clin Endocrinol (Oxf). 2004; 61(1):81-87.
84. Fisker S, Vahl N, Hansen TB, et al. Serum leptin is increased in growth hormone-deficient adults: relationship to body composition and effects of placebo-controlled growth hormone therapy for 1 year. Metabolism. 1997;46(7):812-817.
85. Florkowski CM, Collier GR, Zimmet PZ, Livesey JH, Espiner EA, Donald RA. Low-dose growth hormone replacement lowers plasma leptin and fat stores without affecting body mass index in adults with growth hormone deficiency. Clin Endocrinol (Oxf). 1996;45(6): 769-773.
86. Berneis K, Vosmeer S, Keller U. Effects of glucocorticoids and of growth hormone on serum leptin concentrations in man. Eur J Endocrinol. 1996;135(6):663-665.
87. López-Siguero JP, López-Canti LF, Espino R, et al. Effect of recombinant growth hormone on leptin, adiponectin, resistin, interleukin-6, tumor necrosis factor-β and ghrelin levels in growth hormone-deficient children. J Endocrinol Invest. 2011;34(4):300-306.
88. Conti E, Carrozza C, Capoluongo E, et al. Insulin-like growth factor-1 as a vascular protective factor. Circulation. 2004;110(15): 2260-2265.
89. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Simoons ML, Zeiher AM. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. J Am Coll Cardiol. 2005;45(2):229-237.
90. Fialová L, Pilecková N, Bauer J, et al. Pregnancy-associated plasma protein-A in patients with cerebrovascular diseases- A pilot study. Prague Med Rep. 2006;107(1):37-45.
91. Joaquin C, Aguilera E, et al. Effects of GHtreatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur J Endocrinol. 2008;158(4):483-490.
92. Li L, Ren W, Li J, et al. Increase in serum pregnancy-associated plasma protein-A is correlated with increase in cardiovascular risk factors in adult patients with growth hormone deficiency. Endocrine. 2012;42(2):375-381.
93. Smith JC, Lang D, McEneny J, et al. Effects of GH on lipid peroxidation and neutrophil superoxide anion-generating capacity in hypopituitary adults with GH deficiency. Clin Endocrinol (Oxf). 2002;56(4):449-455.
94. González-Duarte D, Madrazo-Atutxa A, Soto-Moreno A, Leal-Cerro A. Measurement of oxidative stress and endothelial dysfunction in patients with hypopituitarism and severe deficiency adult growth hormone deficiency. Pituitary. 2012;15(4):589-597.
95. Ozbey N, Telci A, Cakatay U, Yurci A, Molvalilar S. Determination of oxidative protein and lipid damage in adult hypopituitary patients with GH deficiency. J Endocrinol Invest. 2003;26(10):1001-1007.
96. Scacchi M, Valassi E, Pincelli AI, et al. Increased lipid peroxidation in adult GH-deficient patients: effects of short-term GH administration. J Endocrinol Invest. 2006;29(10):899-904.
97. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll Cardiol. 2012;60(10):932-942.
98. Jax TW, Peters AJ, Plehn G, Schoebel FC. Hemostatic risk factors in patients with coronary artery disease and type 2 diabetes - a two year follow-up of 243 patients. Cardiovasc Diabetol. 2009;8:48.
99. Cakir I, Tanriverdi F, Karaca Z, et al. Evaluation of coagulation and fibrinolytic parameters in adult onset GH deficiency and the effects of GH replacement therapy: a placebo controlled study. Growth Horm IGF Res. 2012;22(1):17-21.
100. Beshyah SA, Markussis V, Harbourne T, Nicolaides AN, Johnston DG. Haemostatic mechanisms are normal despite increased vascular mortality in hypopituitary adults. Horm Metab Res. 1993; 25(8):449-450.
101. Gómez JM, Sahún M, Vila R, et al. Peripheral fibrinolytic markers, soluble adhesion molecules, inflammatory cytokines and endothelial function in hypopituitary adults with growth hormone deficiency. Clin Endocrinol (Oxf.) 2006;64(6):632-639.
102. Kvasnicka J, Marek J, Kvasnicka T, et al. Increase of adhesion molecules, fibrinogen, type-1 plasminogen activator inhibitor and orosomucoid in growth hormone (GH) deficient adults and their modulation by recombinant human GH replacement. Clin Endocrinol (Oxf). 2000;52(5):543-548.
103. Johansson JO, Landin K, Johannsson G, Tengborn L, Bengtsson BA. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults. Thromb Haemost. 1996;76(3): 422-428.
104. Gazzaruso C, Coppola A, Giustina A. Erectile dysfunction and coronary artery disease in patients with diabetes. Curr Diabetes Rev. 2011;7(2):143-147.
105. Siervo M, Corander M, Stranges S, Bluck L. Post-challenge hyperglycaemia, nitric oxide production and endothelial dysfunction: the putative role of asymmetric dimethylarginine (ADMA). Nutr Metab Cardiovasc Dis. 2011;21(1):1-10.
106. Krzyzanowska K, Mittermayer F, Schnack C, Hofer M, Wolzt M, Schernthaner G. CirculatingADMAconcentrations are elevated in hypopituitary adults with and without growth hormone deficiency. Eur J Clin Invest. 2005;35(3):208-213.
107. Setola E, Monti LD, Lanzi R, et al. Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency. Metabolism. 2008;57(12):1685-1690.
108. Juárez-Orozco LE, Glauche J, Alexanderson E, et al. Myocardial perfusion reserve in spared myocardium: correlation with infarct size and left ventricular ejection fraction. Eur J Nucl Med Mol Imaging. 2013;40(8):1148-1154.
109. Giubbini R, Bertagna F. Myocardial perfusion reserve in spared myocardium: one more tessera of the complex mosaic of LV remodelling after myocardial infarction. Eur J Nucl Med Mol Imaging. 2013;40(8):1146-1147.
110. Moisey R, Orme S, Barker D, et al. Cardiac functional reserve is diminished in growth hormone-deficient adults. Cardiovasc Ther. 2009;27(1):34-41.
111. Groban L, Lin M, Kassik KA, Ingram RL, Sonntag WE. Early-onset growth hormone deficiency results in diastolic dysfunction in adult-life and is prevented by growth hormone supplementation. Growth Horm IGF Res. 2011;21:81-88.
112. Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation. 2003;108:2648-2652.
113. Cenci MC, Soares DV, Spina LD, et al. Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH deficiency. Pituitary. 2009;12:322-329.
114. Andreassen M, Faber J, Kjaer A, Petersen CL, Kristensen LØ. Cardiac function in growth hormone deficient patients before and after 1 year with replacement therapy: a magnetic resonance imaging study. Pituitary. 2011;14:1-10.
115. Gruson D, Alexopoulou O, Pasquet A, Cumps J, Ketelslegers JM, Maiter D. Impact of growth hormone (GH) treatment on circulating Nt-pro BNP concentrations and on cardiac function in adult GH-deficient patients. Scand J Clin Lab Invest. 2012; 72:387-394.
116. Cenci MC, Soares DV, Spina LD, et al. Comparison of two dose regimens of growth hormone (GH) with different target IGF-1 levels on glucose metabolism, lipid profile, cardiovascular function and anthropometric parameters in GH-deficient adults. Growth Horm IGF Res. 2012;22:116-121.
117. Newman CB, Frisch KA, Rosenzweig B, et al. Moderate doses of hGH(0.64 mg/d) improve lipids but not cardiovascular function in GH-deficient adults with normal baseline cardiac function. J Clin Endocrinol Metab. 2011;96:122-132.
118. Rosén T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990;336(8710):285-288.
119. Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab. 1996; 81(3):1169-1172.
120. Bülow B, Hagmar L, Mikoczy Z, Nordström CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf). 1997;46(1):75-81.
121. Svensson J, Bengtsson BA, Rosén T, Odén A, Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab. 2004;89(7):3306-3312.
122. Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001;357(9254): 425-431.
123. Burman P, Mattsson AF, Johannsson G, et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J Clin Endocrinol Metab. 2013;98(4):1466-1475.
124. Stochholm K, Laursen T, Green A, et al. Morbidity and GH deficiency: a nationwide study. Eur J Endocrinol. 2008;158(4):447-457.
125. Vliegenthart R, Morris PB. Computed tomography coronary artery calcium scoring: review of evidence base and cost-effectiveness in cardiovascular risk prediction. J Thorac Imaging. 2012;27(5): 296-303.
126. Cannavò S, Marini F, Curtò L, et al. High prevalence of coronary calcifications and increased risk for coronary heart disease in adults with growth hormone deficiency. J Endocrinol Invest. 2011;34(1): 32-37.
127. Schneider HJ, Klotsche J, Wittchen HU, et al. Effects of growth hormone replacement within the KIMS survey on estimated cardiovascular risk and predictors of risk reduction in patients with growth hormone deficiency. Clin Endocrinol (Oxf). 2011;75(6): 825-830.
128. Monson JP. Long-term experience with GH replacement therapy: efficacy and safety. Eur J Endocrinol. 2003;148(suppl 2): S9-S14.
129. van Bunderen CC, van Nieuwpoort IC, Arwert LI, et al. Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in adults. J Clin Endocrinol Metab. 2011;96(10):3151-3159.
130. Gaillard RC, Mattsson AF, Akerblad AC, et al. Overall and causespecific mortality in GH-deficient adults on GH replacement. Eur J Endocrinol. 2012;166(6):1069-1077.
131. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587-1609.
132. Doga M, Bonadonna S, Gola M, Mazziotti G, Giustina A. Growth hormone deficiency in the adult. Pituitary. 2006;9(4):305-311.
133. Doga M, Bonadonna S, Gola M, et al. Current guidelines for adult GH replacement. Rev Endocr Metab Disord. 2005;6(1):63-70.
134. Giustina A, Barkan A, Chanson P, et al. Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest. 2008;31(9):820-38.
135. Cuneo RC, Salomon F, Wilmshurst P, et al. Cardiovascular effects of growth hormone treatment in growth-hormone-deficient adults: stimulation of the renin-aldosterone system. Clin Sci (Lond). 1991;81(5):587-592.
136. Johannsson G, Bengtsson BA, Andersson B, Isgaard J, Caidahl K. Long-term cardiovascular effects of growth hormone treatment in GH-deficient adults. Preliminary data in a small group of patients. Clin Endocrinol (Oxf). 1996;45(3):305-314.
137. Johannsson G, Rosén T, Bengtsson BA. Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol (Oxf). 1997;47(5):571-581.
138. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008;29(5):535-559.
139. Mazziotti G, Gola M, Bianchi A, et al. Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine. 2011;40(1):102-108.
140. Melmed S, Casanueva FF, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary. 2013;16(3):294-302.
141. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2007;92(5):1743-1747.
142. Giustina A, Casanueva FF, Cavagnini F, et al. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest. 2003; 26(12):1242-1247.
143. Mazziotti G, Bianchi A, Bonadonna S, et al. Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Miner Res. 2006;21(4):520-528.
144. Attanasio AF, Lamberts SW, Matranga AM, et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab. 1997;82(1):82-88.
145. Mazziotti G, Porcelli T, Bianchi A, et al. Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol. 2010;163(1):15-20.
146. Giustina A. Does growth hormone replacement therapy improve cardiac function? Nat Clin Pract Endocrinol Metab. 2007;3(9):614-615.